Effect of l -Dopa in acute temozolomide-induced cognitive impairment in male mice: a possible antineuroinflammatory role.
Behav Pharmacol
; 34(5): 263-274, 2023 08 01.
Article
em En
| MEDLINE
| ID: mdl-37401406
ABSTRACT
Temozolomide is used commonly in the treatment of some types of cancers, but it may also result in cognitive impairments such as memory deficits. l -Dopa, a well known medicine for the central nervous system, has been shown to have positive effects on some cognitive disorders. Here we sought to investigate the effect of l -Dopa on temozolomide-induced cognitive impairments. BALB/c mice were subjected to 3-days temozolomide and 6-days concomitant l -Dopa/benserazide administration in six groups (control, l -Dopa 25â
mg/kg, l -Dopa 75â
mg/kg, temozolomide, temozolomideâ
+â
l -Dopa 25â
mg/kg, and temozolomideâ
+â
l -Dopa 75â
mg/kg). Open field test, object location recognition, novel object recognition test, and shuttle-box test were carried out to determine the locomotor, anxiety-like behavior, and memory function of subjects. TNF-α and brain-derived neurotrophic factor (BDNF) gene expression in the hippocampus was measured by real-time PCR. Mice treated with temozolomide showed recognition memory impairment, along with hippocampal TNF-α and BDNF mRNA expression level raise, and detection of histological insults in hematoxylin and eosin hippocampal slides. Mice that received temozolomideâ
+â
l -Dopa showed normal behavioral function and lower TNF-α and BDNF hippocampal mRNA expression levels, and histologically normal hippocampal CA1 region in comparison with mice in the temozolomide group. Our results provide evidence that l -Dopa prevents temozolomide-induced recognition memory deficit in mice at the acute phase probably via l -Dopa antineuroinflammatory effects.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Fator Neurotrófico Derivado do Encéfalo
/
Disfunção Cognitiva
Limite:
Animals
Idioma:
En
Revista:
Behav Pharmacol
Assunto da revista:
CIENCIAS DO COMPORTAMENTO
/
FARMACOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article